## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

VETMULIN 125 mg/ml Solution for use in drinking water for pigs and chickens

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

**Active substance:**
Tiamulin hydrogen fumarate 125 mg
(equivalent to tiamulin 101.2 mg)

**Excipients:**

| **Qualitative composition of excipients and other constituents** | **Quantitative composition if that information is essential for proper administration of the veterinary medicinal product** |
|---|---|
| Methyl parahydroxybenzoate (E218) | 0.90 mg |
| Propyl parahydroxybenzoate | 0.10 mg |
| Disodium phosphate anhydrous | |
| Ethanol 96% | |
| Water for injection | |

Clear, colorless to slightly yellow liquid.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Pigs. Chickens (layer hens).

### 3.2 Indications for use for each target species

Pigs:
- Treatment of Swine dysentery caused by *Brachyspira hyodysenteriae* susceptible to tiamulin. The presence of the disease in the herd must be established before the veterinary medicinal product is used.
- Treatment of Porcine Colonic Spirochaetosis (spirochaetal diarrhoea or colitis) caused by *Brachyspira pilosicoli* susceptible to tiamulin. The presence of the disease in the herd must be established before the veterinary medicinal product is used.
- Treatment of Porcine Proliferative Enteropathy (ileitis) caused by *Lawsonia intracellularis*, susceptible to tiamulin. The presence of the disease in the herd must be established before the veterinary medicinal product is used.
- Treatment and metaphylaxis of Enzootic pneumonia caused by *Mycoplasma hyopneumoniae*, including infections complicated by *Pasteurella multocida* susceptible to tiamulin. The presence of the disease in the herd must be established before the veterinary medicinal product is used.

Chickens (layer hens):

- Treatment and metaphylaxis of Chronic Respiratory Disease caused by *Mycoplasma gallisepticum* and Airsacculitis and Infectious Synovitis caused by *Mycoplasma synoviae* susceptible to tiamulin. The presence of the disease in the flock must be established before the veterinary medicinal product is used.

## 3.3 Contraindications

Do not use in animals that could receive products containing monensin, narasin or salinomycin during or for at least seven days before or after treatment with tiamulin. Severe growth depression or death may result.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

See section 3.8 for information regarding interaction between tiamulin and ionophores.

## 3.4 Special warnings

Pigs with reduced water intake and/or in a debilitated condition should be treated parenterally.

Water intake may be depressed during the administration of tiamulin in birds. It appears to be concentration-dependent with 500 mg tiamulin hydrogen fumarate (equivalent to 4ml of veterinary medicinal product) in 4 litres of water reducing intake by approximately 10% and 500 mg tiamulin hydrogen fumarate (equivalent to 4 ml of veterinary medicinal product) in 2 litres of water by 15% in chickens. It does not appear to have any adverse effect on overall performance of the birds or efficacy of the veterinary medicinal product but water intake should be monitored at frequent intervals, especially in hot weather.

## 3.5 Special precautions for use

Special precautions for safe use in the target species:
Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to tiamulin.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to tiamulin or parabens should administer the veterinary medicinal product with caution.

Both the veterinary medicinal product and the diluted veterinary medicinal product in drinking water may cause hypersensitivity reactions due to contact. Avoid contact with the

skin. Do not smoke, eat or drink when mixing and handling the veterinary medicinal product. Personal protective equipment consisting of protective clothes and protective gloves should be worn when handling the veterinary medicinal product. Wash hands after use. In case of accidental contact with skin, rinse with plenty of clean water. Contaminated clothing should be removed.
Ingestion of the veterinary medicinal product or medicated water should be avoided. In the event of accidental ingestion, rinse mouth with plenty of water.
In case of accidental ingestion or spillage onto skin, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:
Not applicable.

## 3.6 Adverse events

Pigs:

| | |
|---|---|
| Very rare (<1 animal / 10.000 animals treated, including isolated report(s)): | Erythema, skin oedema |

Chickens (layer hens):

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

## 3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation
Can be used in pigs during pregnancy and lactation

Laying birds
Can be used in chickens (layer hens).

## 3.8 Interaction with other medicinal products and other forms of interaction

Tiamulin has been shown to interact with ionophores such as monensin, salinomycin and narasin and may result in signs indistinguishable from an ionophore toxicosis. Animals should not receive products containing monensin, salinomycin or narasin during or at least 7 days before or after treatment with tiamulin. Severe growth depression, ataxia, paralysis or death may result. If signs of an interaction do occur, stop both the administration of tiamulin-medicated drinking water and also the administration of ionophore-contaminated feed immediately. The feed should be removed and replaced with fresh feed not containing the

anticoccidials monensin, salinomycin or narasin. Concomitant use of tiamulin and the divalent ionophore anticoccidials lasalocid and semduramicin do not appear to cause any interaction, however the concomitant use of maduramicin may lead to a mild to moderate growth depression in chickens. The situation is transient and recovery normally occurs within 3- 5 days following withdrawal of tiamulin treatment.

## 3.9 Administration routes and dosage

In drinking water use.

Guidance for preparing veterinary medicinal product solutions:
To ensure a correct dosage, body weight should be determined as accurately as possible. The intake of medicated water depends on the clinical condition of the animals. In order to obtain the correct dosage, the concentration of tiamulin may need to be adjusted accordingly.

Based on the recommended dose and the number and weight of animals to be treated, the exact daily concentration of the veterinary medicinal product should be calculated according to the following formula:

$$\frac{\textit{ml veterinary medicinal product/ kg body weight per day} \times \textit{average body weight (kg) of animals to be treated}}{\textit{average daily water intake (l/animal)}} = \textit{ml veterinary medicinal product per litre of drinking water}$$

Use a sufficiently accurate commercially available device to measure the required amount of veterinary medicinal product. Only use clean containers for preparation of the medicated drinking water. Stir the medicated drinking water prepared with the veterinary medicinal product for at least 1 minute after preparation in order to assure homogeneity.
When medicating large volumes of water, prepare a concentrated solution first and then dilute to the required final concentration. The maximum solubility of the veterinary medicinal product is 200 mL/L.

Medicated drinking water should be refreshed or replaced every 24 hours.

In order to avoid interactions between the ionophores and tiamulin, the veterinarian and farmer should check that the feed label does not state that it contains salinomycin, monensin and narasin.
For chickens, in order to avoid interactions between the incompatible ionophores monensin, narasin and salinomycin and tiamulin, the feed mill supplying the birds feed should be notified that tiamulin will be used and that these anticoccidials should not be included in the feed or contaminate the feed.
The feed should be tested for the ionophores prior to use if there is any suspicion that contamination of the feed might occur.
If an interaction does occur, stop tiamulin medication immediately and replace with fresh drinking water. Remove contaminated feed as soon as possible and replace with feed not containing the tiamulin- incompatible ionophores.

Pigs

- For the treatment of Swine Dysentery caused by *Brachyspira hyodysenteriae.*
  The dosage is 8.8 mg tiamulin hydrogen fumarate/kg body weight (equivalent to 7 ml of veterinary medicinal product/100 kg body weight) administered daily in the drinking water of pigs for 3 to 5 consecutive days depending on the severity of the infection and/or the duration of the disease.

- For the treatment of Porcine Colonic Spirochaetosis (colitis) caused by *Brachyspira pilosicoli*. The dosage is 8.8 mg tiamulin hydrogen fumarate /kg body weight (equivalent to 7 ml of veterinary medicinal product/100 kg body weight) administered daily in the drinking water of pigs for 3 to 5 consecutive days depending on the severity of the infection and/or the duration of the disease.

- For the treatment of Porcine Proliferative Enteropathy (ileitis) caused by *Lawsonia intracellularis*. The dosage is 8.8 mg tiamulin hydrogen fumarate /kg body weight (equivalent to 7 ml of veterinary medicinal product/100 kg body weight) administered daily in the drinking water of pigs for 5 consecutive days.

- For the treatment and metaphylaxis of Enzootic Pneumonia caused by *Mycoplasma hyopneumoniae*,including infections complicated by *Pasteurella multocida* susceptible to tiamulin. The dosage is 20 mg tiamulin hydrogen fumarate/kg body weight (equivalent to 16 ml of veterinary medicinal product/100 kg body weight) administered daily for 5 consecutive days.

Chickens (layer hens)

For the treatment and metaphylaxis of Chronic Respiratory Disease caused by *Mycoplasma gallisepticum* and Airsacculitis and Infectious Synovitis caused by *Mycoplasma synoviae*. the dosage is 25 mg tiamulin hydrogen fumarate/kg body weight (equivalent to 20 ml of veterinary medicinal product/100 kg body weight) administered daily for the period of 3 to 5 consecutive days.

**3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Pigs

Single oral doses of 100 mg tiamulin hydrogen fumarate/kg body weight in pigs caused hyperpnoea and abdominal discomfort. At 150 mg tiamulin hydrogen fumarate/kg body weight no central nervous system effects were noted except for sedation. At 55 mg tiamulin hydrogen fumarate/kg body weight given daily for 14 days, a transient salivation and slight gastric irritation occurred. Tiamulin hydrogen fumarate is considered to have an adequate therapeutic index in the pig and a minimum lethal dose has not been established.

Chickens

The $LD_{50}$ is 1090 mg/kg body weight for chickens. There is a relatively high therapeutic index with tiamulin hydrogen fumarate and the likelihood of an overdose is considered remote especially as water intake and hence tiamulin hydrogen fumarate intake is reduced if abnormally high concentrations are given. The clinical signs of acute toxicity in chickens are vocalisation, clonic cramps and lying in a lateral position.

If signs of intoxication do occur promptly remove the medicated water and replace with fresh unmedicated water and apply supportive, symptomatic therapy.

## 3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

## 3.12 Withdrawal periods

Pigs:

Meat and offal: 2 days (8.8 mg tiamulin hydrogen fumarate/ kg body weight equivalent to 7 ml of veterinary medicinal product/100 kg body weight)
Meat and offal: 4 days (20 mg tiamulin hydrogen fumarate/ kg body weight, equivalent to 16 ml veterinary medicinal product)/100 kg body weight)

Chickens (layer hens):

Meat and offal: 2 days
Eggs: zero days

# 4. PHARMACOLOGICAL INFORMATION

## 4.1 ATC Vet code:

QJ01XQ01

## 4.2 Pharmacodynamics

Tiamulin is a bacteriostatic semi-synthetic antibiotic belonging to the pleuromutilin group of antibiotics and acts at the ribosomal level to inhibit bacterial protein synthesis.

Tiamulin has shown a high level of *in vitro* activity against porcine and avian *Mycoplasma* species as well as gram-positive aerobes (streptococci and staphylococci), anaerobes (clostridia), gram-negative anaerobes (*Brachyspira hyodysenteriae*, *Brachyspira pilosicoli),* and gram-negative aerobes (*Pasteurella multocida*).

Tiamulin has been shown to act at the 70S ribosome level and the primary binding sites are on the 50S subunit. It appears to inhibit microbial protein production by producing biochemically inactive initiation complexes, which prevent elongation of the polypeptide chain.

In European isolates of *Brachyspira hyodysenteriae* collected between 1990 and 2012 the minimum inhibitory concentration (MICs) ranged from ≤0.016 µg/ml to >16 µg/ml, with $MIC_{50}$ of ≤0.063 µg/ml to 4 µg/ml and $MIC_{90}$ of ≤0.016 µg/ml to >16 µg/ml.

In European isolates of *Brachyspira pilosicoli* the MICs ranged from (citation from 2006-2008-2012) ≤0.008-64 µg/ml, with $MIC_{50}$s of ≤0.062 µg/ml up to 0.125 µg/ml and $MIC_{90}$s of 0.25 µg/ml up to 8 µg/ml.

Susceptibility testing of *Lawsonia intracellularis* is challenging since this is an obligate intracellular organism. The tiamulin MIC data determined for the available EU *Lawsonia* strains were (citation from 2017) all below the estimated ileal tiamulin contents of 0.63 µg/ml.

In European isolates tiamulin was highly active against *Mycoplasma hyopneumoniae,* with $MIC_{50}$ of 0.016 µg/ml, $MIC_{90}$ of 0.062 µg/ml, and a MIC range of 0.002-0.125 µg/ml (citation from 2014).

In newer European strains (2005-2013) and older global isolates (before 1997) MIC ranges were similar for *Mycoplasma gallisepticum* ranging from 0.001 – 0.037 µg/ml with $MIC_{50}$s of 0.001 and 0.008 µg/ml and $MIC_{90}$s of 0.025 and 0.031 µg/ml. No resistant strains were found. For *Mycoplasma synoviae* MICs ranged from 0.05 to 0.5 µg/ml with $MIC_{50}$s of 0.1 µg/ml and a $MIC_{90}$ of 0.25 µg/ml.

## 4.3 Pharmacokinetics

Pigs

Tiamulin hydrogen fumarate is well absorbed in the pig (over 90%) following oral administration and widely distributed through the body. Following a single oral dose of 10 mg and 25 mg tiamulin hydrogen fumarate/kg body weight the $C_{max}$ was 1.03 µg/ml and 1.82 µg/ml in serum respectively by microbiological assay and the $T_{max}$ was 2 hours for both. It has been shown to concentrate in the lung, polymorphonuclear leucocytes and also in liver, where it is metabolised and excreted (70-85%) in the bile, the remainder is excreted via the kidney (15-30%). Serum protein binding is approximately 30%. Tiamulin, which has not been absorbed or metabolised, passes down the intestines to the colon. Colon contents concentrations of tiamulin have been estimated at 3.41 µg/ml following administration of tiamulin hydrogen fumarate at 8.8 mg/kg body weight.

Chickens (layer hens)

Tiamulin hydrogen fumarate is well absorbed in chickens (70-95%) after oral administration and reaches peak concentrations in 2-4 hours ($T_{max}$ 2.85 hours). Following a 50 mg tiamulin hydrogen fumarate/kg body weight single dose the $C_{max}$ was 4.02 µg/ml in serum by microbiological assay and after a 25 mg/kg dose it was 1.86 µg/ml. In drinking water the 250 ppm (0.025%) tiamulin hydrogen fumarate concentration provided a rolling serum level over a 48 hour medication period of 0.78 µg/ml (range 1.4-0.45 µg/ml) and at 125 ppm (0.0125%), 0.38 µg/ml (range 0.65-0.2 µg/ml) in eight-week old chickens. Serum protein-binding was approximately 45%. It distributes widely through the body and has been shown to concentrate in the liver and kidney (sites of excretion) and in the lung (30 times serum level). Excretion is mainly via the bile (55-65%) and kidney (15-30%) as mainly microbiologically inactive metabolites and is quite rapid, 99% of the dose within 48 hours.

### Environmental properties

Tiamulin only degrades slowly in soils and may accumulate over years.

## 5. PHARMACEUTICAL PARTICULARS

## 5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## 5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 3 months.
Shelf life after dilution in drinking water according to directions: 24 hours

## 5.3 Special precautions for storage

Store in the original container in order to protect from light.

## 5.4 Nature and composition of immediate packaging

The veterinary medicinal product is presented in:
- 1 litre high density polyethylene (HDPE) bottle closed with polypropylene (PP) screw cap and low density polyethylene (LDPE) seal disc.
- 5 litre high density polyethylene (HDPE) jar, closed with HDPE ribbed cap with a tamper-evident ring

Not all pack sizes may be marketed.

## 5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## 6. NAME OF THE MARKETING AUTHORISATION HOLDER

Huvepharma NV

## 7. MARKETING AUTHORISATION NUMBER(S)

VPA10782/009/002

## 8. DATE OF FIRST AUTHORISATION

04 April 2019

## 9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

23 October 2024

## 10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).